How do you weigh the risks of re-treatment with infliximab in a patient who has been off it for over a year?  

To answer this question, we first need to go back in time. Treatment with infliximab has been known to elicit the formation of antibodies against infliximab. The presence of these antibodies has been associated with infusion reactions in 7-19 % of patients and may also shorten the duration of the ef...

I am generally comfortable restarting infliximab therapy after a gap in time (assuming the reason for stopping in the first place was not lack of response) when the patient was taking concomitant immunomodulatory therapy during the first course, for the reasons Dr. @Helfgott outlined. When a patient...